Members only publications are marked with a lock icon:
Filter By
Clinical Alerts
May 10, 2016

FDA is warning that the antipsychotic medicine olanzapine can cause a rare but serious skin reaction that can progress to affect other parts of the body. FDA is adding a new warning to the drug labels for all olanzapine-containing products that describes this severe condition known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Clinical Alerts
April 19, 2016


  1. Why get vaccinated for pneumococcal disease?
    The most effective way to treat pneumococcal disease is to prevent it through immunization.

    Pneumococcal disease is a common, yet potentially serious infection caused by Streptococcus pneumoniae bacteria. Streptococcus pneumoniae is the leading cause of serious community-acquired illness worldwide. In addition to being the most common cause of community acquired pneumonia, it also causes invasive
  2. ...
Clinical Alerts
April 8, 2016

AUDIENCE: Pharmacy, Nephrology, Internal Medicine, Patient

ISSUE: FDA is requiring labeling changes regarding the recommendations for metformin-containing medicines for diabetes to expand metformin's use in certain patients with reduced kidney function. The current labeling strongly recommends against use of metformin in some patients whose kidneys do not work normally. FDA was asked to review numerous medical studies regarding the safety of metformin use in patients with mild to moderate impairment in kidney function, and to change the measure of...

Clinical Alerts
December 24, 2015

From: Federal Practitioner
View the full article, with tables and graphics here.

Federico Perez, MD; Robin L.P. Jump, MD, PhD
Dr. Perez and Dr. Jump are physicians and researchers at the Louis Stokes VAMC and assistant professors of medicine at Case Western Reserve University...

Clinical Alerts
April 30, 2015


On August 13, 2014, the Advisory Committee on Immunization Practices (ACIP) met and approved changes to their recommendations for pneumococcal vaccination. Of note, the ACIP now recommends the routine use of 13-valent pneumococcal conjugate vaccine (PCV 13) in adults ≥ 65 years of age in addition to the 23-valent pneumococcal polysaccharide vaccine (PPV23).1

AMDA - The Society for Post-Acute and Long-Term Care Medicine has received a number of inquiries regarding questions of policy coverage owing to the complexity of the...